DelveInsight’s, “Notch Receptor Antagonists – Pipeline Insight, 2022,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Notch Receptor Antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Notch Receptor Antagonists: Overview
Notch is a key player in various developmental processes during the embryonic stage as well as in regulating tissue homeostasis, cell differentiation, and stem cell maintenance in adult life. Activation of Notch signaling occurs following Notch receptor-ligand interaction and subsequent enzymatic proteolysis by the gamma-secretase complex, resulting in the cytoplasmic release of a Notch intracellular domain, which translocates to the nucleus to initiate the downstream transcriptional machinery. Notch activation and its aberrant signaling have been broadly linked to the pathogenesis of cancer and some chronic inflammatory diseases resulting in pathologic fibrotic processes. Based on the molecular structure of Notch receptor, Notch ligands and Notch activators, a set of Notch pathway inhibitors have been developed. Most of these inhibitors had shown anti-tumor effects in preclinical studies. At the same time, the combinatorial effect of these inhibitors with current chemotherapeutical drugs still under study in different clinical trials.
"Notch Receptor Antagonists - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Notch Receptor Antagonists pipeline landscape is provided which includes the disease overview and Notch Receptor Antagonists treatment guidelines. The assessment part of the report embraces, in depth Notch Receptor Antagonists commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Notch Receptor Antagonists collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Notch Receptor Antagonists R&D. The therapies under development are focused on novel approaches to treat/improve Notch Receptor Antagonists.
This segment of the Notch Receptor Antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Notch Receptor Antagonists Emerging Drugs
AL101: Ayala Pharmaceuticals
AL101 is an investigational small molecule Gamma Secretase Inhibitor (GSI) that is designed to potently and selectively inhibit Notch 1, 2, 3 and 4, and is currently being evaluated in two Phase 2 clinical studies, ACCURACY and TENACITY, in patients with adenoid cystic carcinoma (ACC) and in patients with triple negative breast cancer (TNBC), respectively. AL101 is designed to inhibit the expression of Notch gene targets by blocking the final cleavage step by the gamma secretase required for Notch activation. Ayala obtained an exclusive, worldwide license to develop and commercialize AL101 from Bristol-Myers Squibb Company in November 2017. AL101 was granted U.S. FDA Fast Track Designation and Orphan Drug Designation for the treatment of ACC.
Further product details are provided in the report……..
This segment of the report provides insights about the different Notch Receptor Antagonists drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 4+ key companies which are developing the therapies for Notch Receptor Antagonists. The companies which have their Notch Receptor Antagonists drug candidates in the most advanced stage, i.e. phase II include Ayala Pharmaceuticals.
DelveInsight’s report covers around 4+ products under different phases of clinical development like
Notch Receptor Antagonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Notch Receptor Antagonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Notch Receptor Antagonists drugs.
Current Treatment Scenario and Emerging Therapies:
Introduction
Executive Summary
Notch Receptor Antagonists: Overview
Pipeline Therapeutics
Therapeutic Assessment
Mid Stage Products (Phase II)
AL101: Ayala Pharmaceuticals
Drug profiles in the detailed report…..
Preclinical Stage Products
NADI-351: StemSynergy Therapeutics
Drug profiles in the detailed report…..
Inactive Products
Notch Receptor Antagonists Key Companies
Notch Receptor Antagonists Key Products
Notch Receptor Antagonists- Unmet Needs
Notch Receptor Antagonists- Market Drivers and Barriers
Notch Receptor Antagonists- Future Perspectives and Conclusion
Notch Receptor Antagonists Analyst Views
Notch Receptor Antagonists Key Companies
Appendix
List of Table
Table 1: Total Products for Notch Receptor Antagonists
Table 2: Late Stage Products
Table 3: Mid Stage Products
Table 4: Early Stage Products
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Product Type
Table 7: Assessment by Stage and Product Type
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: Inactive Products
List of Figures
Figure 1: Total Products for Notch Receptor Antagonists
Figure 2: Late Stage Products
Figure 3: Mid Stage Products
Figure 4: Early Stage Products
Figure 5: Preclinical and Discovery Stage Products
Figure 6: Assessment by Product Type
Figure 7: Assessment by Stage and Product Type
Figure 8: Assessment by Route of Administration
Figure 9: Assessment by Stage and Route of Administration
Figure 10: Assessment by Molecule Type
Figure 11: Assessment by Stage and Molecule Type
Figure 12: Inactive Products
• Ayala Pharmaceuticals
• StemSynergy Therapeutics
• OncoMed Pharmaceuticals
• AVEO Oncology
• Eisai Co Ltd
